MYRIAD GENETICS INC's ticker is MYGN and the CUSIP is 62855J104. A total of 289 filers reported holding MYRIAD GENETICS INC in Q2 2014. The put-call ratio across all filers is 3.64 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $2,366,000 | -16.9% | 85,180 | -0.7% | 0.05% | -7.0% |
| Q1 2019 | $2,848,000 | +8.9% | 85,780 | -4.7% | 0.06% | +1.8% |
| Q4 2018 | $2,615,000 | -14.2% | 89,974 | +35.7% | 0.06% | +3.7% |
| Q3 2018 | $3,049,000 | +108.5% | 66,287 | +69.5% | 0.05% | +116.0% |
| Q2 2018 | $1,462,000 | +146100.0% | 39,111 | +205747.4% | 0.02% | – |
| Q1 2018 | $1,000 | 0.0% | 19 | 0.0% | 0.00% | – |
| Q4 2017 | $1,000 | -99.8% | 19 | -99.9% | 0.00% | -100.0% |
| Q4 2014 | $599,000 | -12.3% | 17,585 | -0.8% | 0.02% | -16.0% |
| Q3 2014 | $683,000 | -1.0% | 17,720 | -0.1% | 0.02% | -3.8% |
| Q2 2014 | $690,000 | -61.6% | 17,736 | -76.8% | 0.03% | -68.3% |
| Q3 2013 | $1,797,000 | -43.1% | 76,476 | -34.9% | 0.08% | -41.8% |
| Q2 2013 | $3,156,000 | – | 117,460 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,750,000 | $75,900,000 | 2.61% |
| PFM Health Sciences, LP | 2,025,681 | $55,909,000 | 1.90% |
| Tieton Capital Management, LLC | 118,456 | $3,269,000 | 1.83% |
| Altium Capital Management LP | 190,000 | $5,244,000 | 1.45% |
| DISCIPLINED GROWTH INVESTORS INC /MN | 1,846,490 | $50,963,000 | 1.03% |
| EARNEST PARTNERS LLC | 6,316,365 | $174,332,000 | 1.01% |
| Glenview Capital Management | 1,679,747 | $46,361,000 | 0.99% |
| Zebra Capital Management LLC | 14,209 | $392,000 | 0.63% |
| AIMZ Investment Advisors, LLC | 44,185 | $1,220,000 | 0.48% |
| Phocas Financial Corp. | 132,101 | $3,646,000 | 0.46% |